Synthetic Biology an Overview of the Debates
Total Page:16
File Type:pdf, Size:1020Kb
SYNTHETIC BIOLOGY PROJECT / SYNBIO 3 SYNTHETIC BIOLOGY Ethical Issuesin SYNBIO 3/JUNE2009 An overview ofthedebates Contents Preface 3 Executive Summary 4 Who is doing what, where are they doing it and how is this current work funded? 6 How distinct is synthetic biology from other emerging areas of scientific and technological innovation? 9 Ethics: What harms and benefits are associated with synthetic biology? 12 The pro-actionary and pre-cautionary frameworks 18 N OVERVIEW OF THE DEBATES N OVERVIEW OF A Competing—and potentially complementary—views about non-physical harms (harms to well-being) 23 The most contested harms to well-being 25 Conclusion: Moving the debate forward 26 References 29 ETHICAL ISSUES IN SYNTHETIC BIOLOGY: ETHICAL ISSUES IN SYNTHETIC BIOLOGY: ii The opinions expressed in this report are those of the authors and do not necessarily reflect views Sloan Foundation. Wilson International Center for Scholars or the Alfred P. of the Woodrow Ethical Issues in SYNTHETIC BIOLOGY An overview of the debates Erik Parens, Josephine Johnston, and Jacob Moses The Hastings Center, Garrison, New York SYNBIO 3 / JUNE 2009 2 ETHICAL ISSUES IN SYNTHETIC BIOLOGY: AN OVERVIEW OF THE DEBATES Preface Synthetic biology will allow scientists and where such topics are divided into two broad engineers to create biological systems categories: concerns about physical and non- that do not occur naturally as well as to physical harms. While physical harms often re-engineer existing biological systems to trigger debates about how to proceed among perform novel and beneficial tasks. This researchers, policymakers, and the public, emerging field presents a number of non-physical harms present more difficult opportunities to address ethical issues early conundrums. These non-physical concerns and proactively. range from equitable distribution of benefits to fundamental beliefs about our place in the With synthetic biology, scientists are literally natural world. getting to the basis of life itself, but concerns about whether or not humans should be Ethical concerns are too often addressed “playing god” are only part of the equation. after investments in science have been made Concerns have already been voiced about and technologies are already mature and patents, oversight, and possible inequitable in the marketplace. At that point, neither access to new and potentially powerful the research community nor policymakers synthetic biology innovations in areas ranging have a strong incentive to address ethical from medicine to energy production. issues for fear that any debate may stifle technological advance and innovation. But This report by Erik Parens, Josephine Johnston, given the rate at which new technologies are and Jacob Moses of the Hastings Center, a emerging and converging, this paper argues bioethics research institute in Garrison, New that a comprehensive ethical approach is York, presents a framework for addressing needed early to best foster the wide public the social and ethical issues surrounding the acceptance and support of new technologies emerging field of synthetic biology. The paper such as synthetic biology. explores current frameworks for evaluating ethical issues and proposes an approach —David Rejeski Director, Synthetic Biology Project 3 Executive Summary • To advance knowledge and create • As emerging technologies converge, it • We can expect that ethical concerns will products that can promote human becomes clearer that the ethical issues arise with the advent of any emerging welfare, synthetic biologists seek to raised by these technologies are at technology. These concerns can crudely create biological systems that do not core similar and familiar. It would be a be divided into two large categories: occur naturally as well as to re-engineer waste of resources to take up the ethical concerns about physical harms and biological systems that do occur naturally. questions in parallel; i.e., it is not profitable concerns about non-physical harms. to invent a “new kind” of ethics for each Because “non-physical harms” captures • Synthetic biology can be considered an new technology. Instead, we need to get such a wide range of concerns, it can extension of genetic engineering, which, better at productively engaging the familiar be helpful to further divide non-physical as it advances, will increasingly converge ethical questions that cut across those harms into two groups: those that seem with nano and information technologies. emerging—and converging—technologies. to have gained traction among the Several putatively distinct areas of It is time to go from speaking about researchers closest to the action (e.g., N OVERVIEW OF THE DEBATES N OVERVIEW OF emerging science and technology are hyphenated ethical enterprises (gen- concerns about how to fairly distribute A converging, making it ever less useful to ethics, nano-ethics, neuro-ethics, synbio- the tools needed to do synthetic biology try to draw clear borders among them. ethics) to speaking about the ethics of and how to fairly distribute the benefits of emerging technologies. synthetic biology) and those that have not gained traction among the researchers and scholars closest to the action (primarily concerns about the appropriate attitude to adopt toward ourselves and the rest of the natural world). ETHICAL ISSUES IN SYNTHETIC BIOLOGY: ETHICAL ISSUES IN SYNTHETIC BIOLOGY: 4 • We can also anticipate that people • So far, the literature on synthetic biology • There is a need to identify and engage will often (though not always and not contains significant work on safety and with both physical and non-physical necessarily) think about these ethical security (i.e., physical harms), in which the harms, including those that are deeply concerns using, crudely speaking, two pro-actionary stance has been winning contested. Such an engagement will lead frameworks: a “pro-actionary” or a “pre- the day. That literature also shows some to greater mutual understanding, which is cautionary” framework. People using recognition of the importance of the first both a good in itself and carries practical each framework can give reasons for their kind of non-physical harm and a few benefits. views, but no one proceeds from reasons measures to address some of these harms alone. Noticing that people can proceed (for instance, calls for making patentable • With few exceptions, in the United States from different ethical frameworks can help inventions open-source). But there has we have required policy makers to us better appreciate the disagreements been little meaningful engagement with consider concerns about physical harms, regarding whether the risks of physical and the second kind of non-physical harm, but expected them to remain largely silent non-physical harms are serious and what which depends on even more deeply regarding non-physical harms. Given actions should be taken in response to contested views about the appropriate role the ardency with which concerns about those risks. of humans in relation to themselves, other non-physical harms continue to bubble creatures and the environment. Some up in the public conversation about go so far as to argue that it is not worth emerging technologies, it is time to have a engaging with these concerns. systematic look at the question, what role can concerns about non-physical harms play in the policy world? We do not fully answer that question in this document, but take it to be central for our future research. 5 Who is doing what, where are they doing it and how is this current work funded? INTRODUCTION It is difficult to find a hard-and-fast definition students. He also co-founded the gene of synthetic biology, given both the range of synthesis company Codon Devices. Codon Naturally occurring biological systems activities it involves and the frequent overlap Devices lists Flagship Ventures, Alloy Ventures, are even more complex and difficult to between synthetic biology and other fields of Khosla Ventures, Kleiner Perkins Caufield and 9 manipulate than anyone imagined 10 or research and technology. One way to begin to Byers and Highland Capital as investors. 20 years ago. There are myriad technical understand this range of activity is to look at the problems in getting these systems to act work of the field’s key players (indeed, the field Endy is working at what Maureen O’Malley the way we want. With synthetic biology, is still young enough so that we can identify et al. have called DNA-based device 7 however, scientists hope to leapfrog these four of the key players). These individuals come construction. He is spearheading an effort problems. One of synthetic biologists’ from different disciplines (including engineering to construct and catalogue a registry of what hopes is that by building biological and genetics), have different sources of he calls “biobricks,” which are made from systems from the ground up, they can funding, approach the topic from different DNA and other molecules and can in turn create biological systems that will function angles (creating biobricks out of DNA and be used by other researchers (on an open- like computers or factories, producing the other molecules, engineering whole genomes, source basis) to build what they want. 7 products we want, when we want and in creating cells) and have different goals (from the amounts we want.1,2 (Such industrial understanding the evolution of life to creating Endy’s catalogue of biobricks can be thought useful products like ethanol or artemisinin).8 of as bio-parts that, for example, will reliably N OVERVIEW OF THE DEBATES N OVERVIEW OF analogies are inescapable when talking A about this work, and while they do not turn gene production on or off, or as bio-tools appropriately capture the “living” element Drew Endy, who left the Massachusetts that, for example, will reliably measure the of synthetic biology, they do exemplify the Institute of Technology (MIT) for Stanford concentration of a particular gene product. field’s central goal: to make biology easier University in 2008, is one of those key players.